HSCS (HeartSciences) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSCS HeartSciences Inc HSCS
24 GF Score
Price $2.09
GF Value $0.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is HeartSciences Short-term investments?

Short-term investments only applies to insurance companies.

HSCS
24GF Score
HeartSciences Inc HSCS
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.09 is trading 280% above its estimated GF Value™ of $0.55. GuruFocus considers HeartSciences to be Significantly Overvalued.

Key valuation signals for HSCS:

  • Short-term investments:
  • GF Value™: $0.55 vs. price of $2.09 (280% above fair value)
  • GF Score™: 24/100 with 8 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
24GF Score

Get the complete analysis for HSCS

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.09
Price
$0.55
GF Value